불면증 시장 규모, 점유율 및 성장 분석 : 치료법별, 불면증 유형별, 약제 클래스별, 최종사용자별, 환자층별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Insomnia Market size was valued at USD 4.87 Billion in 2024 and is poised to grow from USD 5.17 Billion in 2025 to USD 8.37 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).

The global insomnia market focuses on products that diagnose, treat, and manage sleep disturbances, including medications, supplements, and wearables. Insomnia is linked to various chronic illnesses, reduced productivity, and rising healthcare costs worldwide, which underscores the market's significance. A key driver of growth is the increasing prevalence of sleep disorders, often exacerbated by heightened media consumption and rising stress levels from work and personal life. Traditional treatments, primarily benzodiazepines, are giving way to safer alternatives like orexin antagonists, melatonin, and behavioral therapies. The market is shifting towards technology-based solutions, including digital therapeutics and personalized, evidence-based interventions. The integration of mobile applications and corporate wellness programs is facilitating market expansion, promoting non-medication approaches and enhancing patient engagement in their own sleep health.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insomnia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insomnia Market Segments Analysis

Global insomnia market is segmented by treatment type, insomnia type, drug class, end user, patient group, distribution channel and region. Based on treatment type, the market is segmented into Pharmacological Treatment, Cognitive Behavioral Therapy, Medical Devices and Others. Based on insomnia type, the market is segmented into Acute Insomnia, Chronic Insomnia and Comorbid Insomnia. Based on drug class, the market is segmented into Benzodiazepines, Dual Orexin Receptor Antagonists, Melatonin Receptor Agonists and Others. Based on end user, the market is segmented into Hospitals, Sleep Clinics, Homecare Settings and Others. Based on patient group, the market is segmented into Adult Patients and Geriatric Patients. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insomnia Market

The increasing recognition of sleep health among the public and healthcare professionals is driving more people to pursue evaluations and management solutions for insomnia, thereby enlarging the patient population for various therapeutic products and services. This growing awareness leads to proactive measures, facilitates early diagnoses, and encourages the use of evidence-based treatments, all of which boost demand across the pharmaceutical, device, and behavioral sectors of the market. Additionally, healthcare providers are incorporating sleep assessments into standard check-ups, which helps normalize treatment methods and expands market access through collaborative efforts among different medical disciplines.

Restraints in the Global Insomnia Market

The global insomnia market faces significant restraints primarily due to limited coverage for medications, behavioral therapies, and innovative treatments by various healthcare providers and insurers. This lack of comprehensive insurance can lead to high out-of-pocket expenses, prompting individuals to rely on over-the-counter remedies or to avoid seeking treatment entirely, which in turn stifles demand for higher-quality products and services. These financial obstacles impede the market's penetration and hinder the acceptance of new interventions, ultimately affecting revenue opportunities for manufacturers and healthcare providers involved in the insomnia industry. Additionally, the absence of standardized coding for sleep services creates challenges in reimbursement, further discouraging provider participation.

Market Trends of the Global Insomnia Market

The global insomnia market is experiencing a significant transformation driven by the rise of digital therapies and mobile sleep-tracking technologies. This trend is characterized by the integration of AI-driven personalization in cognitive-behavioral interventions, enabling consumers to access tailored therapeutic solutions via their smartphones. As reliance on traditional pharmacologic treatments diminishes, engagement levels among patients rise, fostering a shift toward subscription-based revenue models. With growing clinician endorsement of evidence-based digital solutions, insurance providers are beginning to recognize their value, facilitating broader market acceptance. Consequently, traditional sleep aid manufacturers are exploring strategic partnerships with technology firms to expand distribution through retail and corporate wellness avenues.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Insomnia Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacological Treatment
• Cognitive Behavioral Therapy
• Medical Devices
• Others

Global Insomnia Market Size by Insomnia Type & CAGR (2026-2033)

• Market Overview
• Acute Insomnia
• Chronic Insomnia
• Comorbid Insomnia

Global Insomnia Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Benzodiazepines
• Dual Orexin Receptor Antagonists
• Melatonin Receptor Agonists
• Others

Global Insomnia Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Sleep Clinics
• Homecare Settings
• Others

Global Insomnia Market Size by Patient Group & CAGR (2026-2033)

• Market Overview
• Adult Patients
• Geriatric Patients

Global Insomnia Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Insomnia Market Size & CAGR (2026-2033)

• North America (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurim Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axsome Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harmony Biosciences Holdings, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations